is zepbound a tirzepatide Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity FDA Approves Tirzepatide (Zepbound) as

Published data from tirzepatide withdrawal studies indicate that a significant proportion of lost weight is regained within 12 months of stopping treatment, consistent with the broader pattern observed across the GLP-1 class

The barrage of letters continues a crackdown on companies selling compounded versions of in-patent drugs that started last year, and has already resulted in warnings for prominent telehealth companies offering GLP-1s for weight loss, including Hims & Hers

Jack Shuang Hou This move reinforces AstraZenecas broader #obesity strategy, including its push into #GLP-1/GIP combinations, as competition intensifies in one of pharmas fastest-growing therapeutic areas

10.1002/iub.1646

Navigating Insurance with Klinic Insurance can often be an obstacle when starting GLP-1 weight loss medication